IMO nothing more helpful to investors than a flawed broker report which will temporarily reduce the entry price. Of real interest is the progress made in reducing the deficit and the recognition gained for Cardiocel. Step by step its building up recurring sales. Long journey but once in profit the company won't look back.
Reports and analysis RE: AHZ AR, page-13
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.20 |
Change
-0.550(3.10%) |
Mkt cap ! $330.6M | |||
| Open | High | Low | Value | Volume |
| $17.75 | $17.75 | $16.88 | $199.1K | 11.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $17.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.24 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |